Arny Ferrando
Concepts (330)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Muscle Proteins | 45 | 2024 | 303 | 6.160 |
Why?
| Muscle, Skeletal | 48 | 2024 | 750 | 5.720 |
Why?
| Dietary Proteins | 21 | 2024 | 242 | 5.370 |
Why?
| Amino Acids, Essential | 25 | 2022 | 131 | 4.450 |
Why?
| Amino Acids | 19 | 2023 | 360 | 4.420 |
Why?
| Protein Biosynthesis | 12 | 2021 | 253 | 2.980 |
Why?
| Body Composition | 20 | 2023 | 318 | 1.960 |
Why?
| Bed Rest | 9 | 2009 | 36 | 1.910 |
Why?
| Proteins | 8 | 2022 | 342 | 1.830 |
Why?
| Dietary Supplements | 16 | 2024 | 443 | 1.770 |
Why?
| Muscular Atrophy | 4 | 2021 | 70 | 1.750 |
Why?
| Exercise | 18 | 2024 | 495 | 1.530 |
Why?
| Military Personnel | 5 | 2023 | 159 | 1.530 |
Why?
| Phenylalanine | 12 | 2022 | 128 | 1.410 |
Why?
| Aging | 9 | 2024 | 687 | 1.230 |
Why?
| Quadriceps Muscle | 3 | 2023 | 46 | 1.150 |
Why?
| Isotopes | 3 | 2022 | 23 | 1.090 |
Why?
| Sarcopenia | 4 | 2021 | 84 | 1.060 |
Why?
| Eating | 5 | 2022 | 162 | 1.060 |
Why?
| Arthroplasty, Replacement, Hip | 4 | 2022 | 261 | 1.060 |
Why?
| Kidney Failure, Chronic | 8 | 2010 | 198 | 1.040 |
Why?
| Humans | 94 | 2024 | 49974 | 1.000 |
Why?
| Feeding Behavior | 3 | 2017 | 181 | 1.000 |
Why?
| Meals | 6 | 2021 | 57 | 0.990 |
Why?
| Anabolic Agents | 8 | 2024 | 33 | 0.970 |
Why?
| Muscle Strength | 7 | 2021 | 124 | 0.940 |
Why?
| Renal Dialysis | 7 | 2010 | 169 | 0.910 |
Why?
| Hydrocortisone | 7 | 2012 | 107 | 0.900 |
Why?
| Male | 62 | 2024 | 25241 | 0.890 |
Why?
| Stress, Physiological | 2 | 2019 | 170 | 0.880 |
Why?
| Dietary Carbohydrates | 5 | 2021 | 88 | 0.830 |
Why?
| Testosterone | 7 | 2022 | 139 | 0.820 |
Why?
| Malnutrition | 2 | 2021 | 87 | 0.730 |
Why?
| Postoperative Care | 1 | 2021 | 102 | 0.730 |
Why?
| Muscle Contraction | 2 | 2019 | 105 | 0.730 |
Why?
| Preoperative Care | 1 | 2021 | 164 | 0.700 |
Why?
| Postprandial Period | 6 | 2021 | 69 | 0.680 |
Why?
| Military Medicine | 1 | 2019 | 22 | 0.670 |
Why?
| Burns | 7 | 2012 | 162 | 0.660 |
Why?
| Proteome | 1 | 2020 | 173 | 0.650 |
Why?
| Energy Metabolism | 8 | 2021 | 282 | 0.640 |
Why?
| Aged | 24 | 2022 | 9310 | 0.630 |
Why?
| Adult | 39 | 2022 | 13236 | 0.630 |
Why?
| Occupational Diseases | 1 | 2019 | 89 | 0.630 |
Why?
| Female | 44 | 2023 | 26472 | 0.620 |
Why?
| Breakfast | 1 | 2017 | 15 | 0.600 |
Why?
| Nitrogen | 4 | 2022 | 66 | 0.570 |
Why?
| Insulin | 10 | 2021 | 457 | 0.570 |
Why?
| Middle Aged | 28 | 2022 | 12069 | 0.550 |
Why?
| Hormones | 4 | 2019 | 55 | 0.540 |
Why?
| Glucose | 3 | 2021 | 344 | 0.540 |
Why?
| Diet | 6 | 2022 | 566 | 0.530 |
Why?
| Kinetics | 9 | 2020 | 623 | 0.520 |
Why?
| Muscular Diseases | 2 | 2006 | 58 | 0.510 |
Why?
| Cross-Over Studies | 8 | 2022 | 224 | 0.500 |
Why?
| Leucine | 6 | 2023 | 116 | 0.490 |
Why?
| Insulin Resistance | 2 | 2021 | 264 | 0.460 |
Why?
| Body Mass Index | 8 | 2021 | 652 | 0.460 |
Why?
| Liver Transplantation | 3 | 2020 | 148 | 0.450 |
Why?
| Absorptiometry, Photon | 5 | 2023 | 154 | 0.400 |
Why?
| Triglycerides | 2 | 2009 | 159 | 0.400 |
Why?
| Osteoarthritis | 2 | 2022 | 62 | 0.400 |
Why?
| Tyrosine | 3 | 2022 | 95 | 0.400 |
Why?
| Nutritional Requirements | 3 | 2022 | 66 | 0.380 |
Why?
| Nutritional Status | 3 | 2021 | 141 | 0.370 |
Why?
| Cytokines | 6 | 2015 | 612 | 0.350 |
Why?
| Cushing Syndrome | 1 | 2009 | 10 | 0.350 |
Why?
| Blood Glucose | 5 | 2017 | 439 | 0.340 |
Why?
| Homeostasis | 2 | 2014 | 200 | 0.340 |
Why?
| Myositis | 2 | 2022 | 18 | 0.330 |
Why?
| End Stage Liver Disease | 2 | 2020 | 44 | 0.320 |
Why?
| Immobilization | 2 | 2007 | 14 | 0.320 |
Why?
| Metabolism | 4 | 2020 | 25 | 0.320 |
Why?
| Isotope Labeling | 2 | 2019 | 53 | 0.310 |
Why?
| Nutritional Physiological Phenomena | 1 | 2008 | 22 | 0.310 |
Why?
| Resistance Training | 5 | 2015 | 92 | 0.290 |
Why?
| Muscle Fibers, Slow-Twitch | 1 | 2006 | 12 | 0.280 |
Why?
| Muscle Fibers, Fast-Twitch | 1 | 2006 | 14 | 0.280 |
Why?
| Glucose Transport Proteins, Facilitative | 1 | 2006 | 10 | 0.280 |
Why?
| Food, Formulated | 3 | 2019 | 42 | 0.280 |
Why?
| Double-Blind Method | 7 | 2021 | 681 | 0.280 |
Why?
| Liver Cirrhosis | 2 | 2020 | 218 | 0.280 |
Why?
| Caloric Restriction | 2 | 2020 | 36 | 0.270 |
Why?
| Biopsy, Needle | 2 | 2015 | 183 | 0.260 |
Why?
| Food | 2 | 2020 | 72 | 0.260 |
Why?
| Infusions, Intravenous | 2 | 2021 | 206 | 0.260 |
Why?
| Ecchymosis | 1 | 2004 | 8 | 0.250 |
Why?
| Blood Specimen Collection | 1 | 2004 | 34 | 0.250 |
Why?
| Energy Intake | 4 | 2022 | 170 | 0.240 |
Why?
| Hematoma | 1 | 2004 | 64 | 0.240 |
Why?
| Physical Endurance | 1 | 2024 | 30 | 0.240 |
Why?
| Catheterization | 1 | 2004 | 96 | 0.240 |
Why?
| Body Weight | 3 | 2018 | 513 | 0.230 |
Why?
| Fibrinogen | 1 | 2004 | 31 | 0.230 |
Why?
| Albumins | 1 | 2004 | 31 | 0.230 |
Why?
| Basal Metabolism | 2 | 2020 | 31 | 0.230 |
Why?
| Liver | 3 | 2024 | 1115 | 0.230 |
Why?
| Amino Acid Transport Systems | 1 | 2003 | 5 | 0.230 |
Why?
| Glutamic Acid | 1 | 2004 | 107 | 0.230 |
Why?
| Digestion | 2 | 2020 | 52 | 0.220 |
Why?
| Proteolysis | 2 | 2020 | 94 | 0.220 |
Why?
| Quality of Life | 4 | 2022 | 836 | 0.220 |
Why?
| Musculoskeletal Physiological Phenomena | 1 | 2002 | 7 | 0.210 |
Why?
| Weightlessness | 1 | 2002 | 14 | 0.210 |
Why?
| Obesity | 2 | 2021 | 1113 | 0.210 |
Why?
| Space Flight | 1 | 2002 | 34 | 0.210 |
Why?
| Biological Availability | 2 | 2019 | 122 | 0.210 |
Why?
| Urea | 1 | 2022 | 77 | 0.210 |
Why?
| Menopause | 1 | 2023 | 55 | 0.210 |
Why?
| Oxandrolone | 3 | 2011 | 10 | 0.210 |
Why?
| GTP-Binding Proteins | 1 | 2022 | 90 | 0.210 |
Why?
| Overweight | 2 | 2021 | 219 | 0.200 |
Why?
| Reindeer | 1 | 2021 | 3 | 0.200 |
Why?
| Egg Proteins | 2 | 2021 | 18 | 0.200 |
Why?
| Exercise Therapy | 2 | 2020 | 98 | 0.200 |
Why?
| Sports | 1 | 2022 | 39 | 0.200 |
Why?
| Postoperative Complications | 2 | 2021 | 984 | 0.200 |
Why?
| Food Analysis | 1 | 2021 | 32 | 0.190 |
Why?
| Young Adult | 10 | 2021 | 3958 | 0.190 |
Why?
| Models, Biological | 4 | 2007 | 727 | 0.190 |
Why?
| Osteoarthritis, Knee | 1 | 2022 | 88 | 0.190 |
Why?
| Cross-Sectional Studies | 2 | 2023 | 1557 | 0.190 |
Why?
| Actinidia | 1 | 2020 | 7 | 0.190 |
Why?
| Orthopedic Procedures | 1 | 2021 | 68 | 0.180 |
Why?
| Hyperammonemia | 1 | 2020 | 18 | 0.180 |
Why?
| Hyperphagia | 1 | 2020 | 10 | 0.180 |
Why?
| Hepatic Encephalopathy | 1 | 2020 | 26 | 0.180 |
Why?
| Mitochondria, Muscle | 1 | 2020 | 37 | 0.180 |
Why?
| Ketoconazole | 2 | 2012 | 17 | 0.180 |
Why?
| Fatty Acids, Omega-3 | 1 | 2020 | 28 | 0.180 |
Why?
| Metabolomics | 1 | 2021 | 126 | 0.180 |
Why?
| Mitochondrial Proteins | 1 | 2020 | 90 | 0.180 |
Why?
| Risk Assessment | 1 | 2004 | 1259 | 0.180 |
Why?
| Carbohydrate Metabolism | 1 | 2019 | 26 | 0.180 |
Why?
| Liver Diseases | 1 | 2020 | 78 | 0.170 |
Why?
| Whole Body Imaging | 1 | 2019 | 22 | 0.170 |
Why?
| Autophagy | 1 | 2020 | 169 | 0.170 |
Why?
| Receptors, Tumor Necrosis Factor | 2 | 2018 | 36 | 0.160 |
Why?
| Occupational Health | 1 | 2019 | 68 | 0.160 |
Why?
| Home Care Services | 1 | 2020 | 73 | 0.160 |
Why?
| Motor Activity | 3 | 2010 | 229 | 0.160 |
Why?
| Altitude Sickness | 1 | 2018 | 7 | 0.160 |
Why?
| Mice, Inbred C57BL | 1 | 2024 | 1816 | 0.160 |
Why?
| Sex Factors | 1 | 2020 | 691 | 0.160 |
Why?
| Inflammation | 3 | 2022 | 604 | 0.160 |
Why?
| Arthroplasty, Replacement, Knee | 1 | 2022 | 282 | 0.160 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2004 | 477 | 0.160 |
Why?
| Diet, High-Fat | 1 | 2020 | 222 | 0.150 |
Why?
| Time Factors | 5 | 2021 | 2903 | 0.150 |
Why?
| Altitude | 1 | 2018 | 16 | 0.150 |
Why?
| Leg | 3 | 2011 | 122 | 0.150 |
Why?
| Waiting Lists | 1 | 2018 | 49 | 0.150 |
Why?
| Cardiovascular Diseases | 1 | 2021 | 440 | 0.130 |
Why?
| Risk Factors | 2 | 2019 | 3613 | 0.130 |
Why?
| Age Factors | 3 | 2014 | 1087 | 0.130 |
Why?
| Osteoarthritis, Hip | 1 | 2015 | 25 | 0.120 |
Why?
| Beverages | 2 | 2019 | 68 | 0.120 |
Why?
| Insulin-Like Growth Factor I | 2 | 2007 | 137 | 0.120 |
Why?
| Gene Expression | 3 | 2006 | 609 | 0.120 |
Why?
| Heart Failure | 1 | 2019 | 458 | 0.110 |
Why?
| Animals | 4 | 2024 | 13187 | 0.110 |
Why?
| Weight Loss | 2 | 2018 | 237 | 0.110 |
Why?
| Adolescent | 7 | 2020 | 6356 | 0.110 |
Why?
| Caspase 3 | 2 | 2010 | 97 | 0.100 |
Why?
| Biopsy | 5 | 2020 | 584 | 0.100 |
Why?
| Fasting | 2 | 2020 | 70 | 0.100 |
Why?
| Aged, 80 and over | 5 | 2021 | 3129 | 0.100 |
Why?
| Glucose Clamp Technique | 1 | 2009 | 15 | 0.090 |
Why?
| Glycerol | 1 | 2009 | 15 | 0.090 |
Why?
| Arginine | 2 | 2008 | 179 | 0.090 |
Why?
| Fatty Acids, Nonesterified | 1 | 2009 | 38 | 0.090 |
Why?
| Random Allocation | 2 | 2024 | 281 | 0.090 |
Why?
| Athletes | 2 | 2022 | 103 | 0.080 |
Why?
| Protein-Energy Malnutrition | 1 | 2009 | 19 | 0.080 |
Why?
| Oxidation-Reduction | 2 | 2021 | 322 | 0.080 |
Why?
| Exercise Test | 2 | 2020 | 121 | 0.080 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 142 | 0.080 |
Why?
| Linear Models | 1 | 2009 | 280 | 0.080 |
Why?
| Hypertriglyceridemia | 1 | 2008 | 13 | 0.080 |
Why?
| Administration, Oral | 3 | 2009 | 426 | 0.080 |
Why?
| Oxidative Stress | 2 | 2020 | 770 | 0.080 |
Why?
| Signal Transduction | 2 | 2020 | 1618 | 0.080 |
Why?
| Milk Proteins | 1 | 2009 | 78 | 0.080 |
Why?
| Blotting, Western | 3 | 2010 | 601 | 0.080 |
Why?
| Analysis of Variance | 1 | 2009 | 562 | 0.080 |
Why?
| RNA, Messenger | 3 | 2006 | 1105 | 0.080 |
Why?
| Regional Blood Flow | 2 | 2009 | 108 | 0.070 |
Why?
| Herpesvirus 4, Human | 1 | 2007 | 35 | 0.070 |
Why?
| Human Growth Hormone | 1 | 2007 | 50 | 0.070 |
Why?
| Virus Activation | 1 | 2007 | 32 | 0.070 |
Why?
| Glucose Transporter Type 3 | 1 | 2006 | 4 | 0.070 |
Why?
| Glucose Transporter Type 5 | 1 | 2006 | 5 | 0.070 |
Why?
| Glucose Transporter Type 4 | 1 | 2006 | 23 | 0.070 |
Why?
| Biological Transport | 1 | 2007 | 174 | 0.070 |
Why?
| Glucose Transporter Type 1 | 1 | 2006 | 17 | 0.070 |
Why?
| Amino Acids, Branched-Chain | 1 | 2007 | 38 | 0.070 |
Why?
| Ubiquitin | 2 | 2003 | 45 | 0.070 |
Why?
| Metabolic Diseases | 1 | 2006 | 40 | 0.070 |
Why?
| Health | 1 | 2006 | 25 | 0.070 |
Why?
| Rest | 1 | 2006 | 63 | 0.060 |
Why?
| Hospitalization | 1 | 2009 | 652 | 0.060 |
Why?
| Alanine | 1 | 2004 | 42 | 0.060 |
Why?
| Texas | 1 | 2004 | 137 | 0.060 |
Why?
| Nandrolone | 1 | 2024 | 3 | 0.060 |
Why?
| Reference Values | 1 | 2004 | 310 | 0.060 |
Why?
| Veins | 1 | 2004 | 71 | 0.060 |
Why?
| Inulin | 1 | 2003 | 7 | 0.060 |
Why?
| Arteries | 1 | 2004 | 93 | 0.060 |
Why?
| Critical Illness | 1 | 2006 | 288 | 0.060 |
Why?
| Physical Fitness | 2 | 2018 | 54 | 0.060 |
Why?
| Androgens | 1 | 2024 | 69 | 0.060 |
Why?
| Immunohistochemistry | 1 | 2006 | 973 | 0.060 |
Why?
| Wounds and Injuries | 1 | 2006 | 276 | 0.050 |
Why?
| Electric Impedance | 1 | 2023 | 41 | 0.050 |
Why?
| Osmolar Concentration | 1 | 2003 | 62 | 0.050 |
Why?
| Treatment Outcome | 4 | 2011 | 5141 | 0.050 |
Why?
| Apoptosis | 2 | 2010 | 1101 | 0.050 |
Why?
| Multienzyme Complexes | 1 | 2003 | 34 | 0.050 |
Why?
| Weightlessness Countermeasures | 1 | 2002 | 2 | 0.050 |
Why?
| Cysteine Endopeptidases | 1 | 2003 | 67 | 0.050 |
Why?
| Comorbidity | 1 | 2004 | 615 | 0.050 |
Why?
| Polyesters | 1 | 2022 | 7 | 0.050 |
Why?
| Carbohydrates | 1 | 2022 | 40 | 0.050 |
Why?
| Diuresis | 1 | 2002 | 11 | 0.050 |
Why?
| Prognosis | 2 | 2020 | 1942 | 0.050 |
Why?
| Injections, Intramuscular | 1 | 2002 | 54 | 0.050 |
Why?
| Placebos | 1 | 2002 | 85 | 0.050 |
Why?
| Proteasome Endopeptidase Complex | 1 | 2003 | 114 | 0.050 |
Why?
| Receptors, Androgen | 1 | 2002 | 46 | 0.050 |
Why?
| History, 20th Century | 1 | 2022 | 99 | 0.050 |
Why?
| Muscles | 1 | 2022 | 103 | 0.050 |
Why?
| Arkansas | 2 | 2020 | 1977 | 0.050 |
Why?
| Incidence | 1 | 2004 | 1003 | 0.050 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2018 | 388 | 0.050 |
Why?
| Fibrosis | 1 | 2022 | 179 | 0.050 |
Why?
| Cattle | 1 | 2021 | 210 | 0.050 |
Why?
| Prostate | 1 | 2002 | 117 | 0.050 |
Why?
| Knee Joint | 1 | 2022 | 162 | 0.050 |
Why?
| Neoplasms | 1 | 2011 | 1235 | 0.050 |
Why?
| Glycogen | 1 | 2021 | 41 | 0.050 |
Why?
| Urine | 1 | 2021 | 23 | 0.050 |
Why?
| Meat | 1 | 2021 | 55 | 0.050 |
Why?
| Myocardium | 1 | 2024 | 436 | 0.050 |
Why?
| Food, Fortified | 1 | 2021 | 32 | 0.050 |
Why?
| Plant Proteins | 1 | 2021 | 70 | 0.050 |
Why?
| Prospective Studies | 2 | 2020 | 2364 | 0.050 |
Why?
| Mitochondrial Dynamics | 1 | 2020 | 18 | 0.050 |
Why?
| Geriatric Assessment | 1 | 2021 | 112 | 0.050 |
Why?
| Endothelial Cells | 1 | 2022 | 269 | 0.050 |
Why?
| Ceramides | 1 | 2020 | 28 | 0.050 |
Why?
| Phospholipids | 1 | 2020 | 57 | 0.040 |
Why?
| Algorithms | 1 | 2004 | 615 | 0.040 |
Why?
| Protein Kinases | 1 | 2020 | 71 | 0.040 |
Why?
| Metabolic Clearance Rate | 1 | 2019 | 68 | 0.040 |
Why?
| Respiratory Function Tests | 1 | 2020 | 90 | 0.040 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2020 | 157 | 0.040 |
Why?
| Statistics, Nonparametric | 2 | 2011 | 194 | 0.040 |
Why?
| Anthropometry | 1 | 2020 | 92 | 0.040 |
Why?
| Lipid Metabolism | 1 | 2020 | 175 | 0.040 |
Why?
| Child | 5 | 2012 | 6847 | 0.040 |
Why?
| Fruit | 1 | 2020 | 136 | 0.040 |
Why?
| Kidney | 1 | 2024 | 665 | 0.040 |
Why?
| Molecular Probe Techniques | 1 | 2019 | 9 | 0.040 |
Why?
| Deuterium | 1 | 2019 | 42 | 0.040 |
Why?
| Evaluation Studies as Topic | 1 | 2019 | 107 | 0.040 |
Why?
| Intestinal Absorption | 1 | 2019 | 57 | 0.040 |
Why?
| Oxygen Consumption | 1 | 2019 | 183 | 0.040 |
Why?
| Ileum | 1 | 2019 | 89 | 0.040 |
Why?
| Acute Disease | 1 | 2019 | 366 | 0.040 |
Why?
| Myogenin | 1 | 2018 | 6 | 0.040 |
Why?
| PAX7 Transcription Factor | 1 | 2018 | 10 | 0.040 |
Why?
| Glucose Intolerance | 2 | 2008 | 27 | 0.040 |
Why?
| Gene Expression Profiling | 1 | 2003 | 1032 | 0.040 |
Why?
| Lower Extremity | 2 | 2009 | 88 | 0.040 |
Why?
| Severity of Illness Index | 1 | 2020 | 945 | 0.040 |
Why?
| Pilot Projects | 1 | 2020 | 699 | 0.040 |
Why?
| Athletic Performance | 1 | 2017 | 29 | 0.040 |
Why?
| Interleukin-6 | 2 | 2010 | 264 | 0.040 |
Why?
| Outpatient Clinics, Hospital | 1 | 2015 | 36 | 0.030 |
Why?
| Hospitals, University | 1 | 2015 | 77 | 0.030 |
Why?
| Disease Susceptibility | 1 | 2015 | 89 | 0.030 |
Why?
| Early Diagnosis | 1 | 2015 | 88 | 0.030 |
Why?
| Creatine | 1 | 2014 | 37 | 0.030 |
Why?
| Caffeine | 1 | 2014 | 67 | 0.030 |
Why?
| Mice | 1 | 2024 | 5739 | 0.030 |
Why?
| Reoperation | 1 | 2015 | 454 | 0.030 |
Why?
| 14-alpha Demethylase Inhibitors | 1 | 2012 | 2 | 0.030 |
Why?
| Adipose Tissue | 1 | 2014 | 187 | 0.030 |
Why?
| Gene Expression Regulation | 2 | 2010 | 976 | 0.030 |
Why?
| Acute-Phase Proteins | 1 | 2012 | 24 | 0.030 |
Why?
| Predictive Value of Tests | 1 | 2015 | 903 | 0.030 |
Why?
| Oligonucleotide Array Sequence Analysis | 2 | 2003 | 411 | 0.020 |
Why?
| United States | 1 | 2021 | 4860 | 0.020 |
Why?
| Amino-Acid N-Acetyltransferase | 1 | 2010 | 2 | 0.020 |
Why?
| Protein Modification, Translational | 1 | 2009 | 3 | 0.020 |
Why?
| Hypertrophy | 1 | 2009 | 50 | 0.020 |
Why?
| Antifungal Agents | 1 | 2012 | 339 | 0.020 |
Why?
| Cholesterol, VLDL | 1 | 2008 | 3 | 0.020 |
Why?
| Longitudinal Studies | 1 | 2011 | 688 | 0.020 |
Why?
| Down-Regulation | 1 | 2010 | 348 | 0.020 |
Why?
| Muscle Strength Dynamometer | 1 | 2008 | 12 | 0.020 |
Why?
| Movement | 1 | 2008 | 82 | 0.020 |
Why?
| Cholesterol | 1 | 2008 | 146 | 0.020 |
Why?
| Space Simulation | 1 | 2007 | 2 | 0.020 |
Why?
| Gait | 1 | 2008 | 85 | 0.020 |
Why?
| Virus Latency | 1 | 2007 | 47 | 0.020 |
Why?
| Saliva | 1 | 2007 | 54 | 0.020 |
Why?
| Case-Control Studies | 1 | 2010 | 1131 | 0.020 |
Why?
| Aerobiosis | 1 | 2006 | 14 | 0.020 |
Why?
| Actins | 1 | 2006 | 118 | 0.020 |
Why?
| Anti-Inflammatory Agents | 1 | 2007 | 161 | 0.020 |
Why?
| Hypertension, Renal | 1 | 2005 | 22 | 0.020 |
Why?
| Malondialdehyde | 1 | 2005 | 51 | 0.020 |
Why?
| Follow-Up Studies | 1 | 2011 | 2182 | 0.020 |
Why?
| Peptide Fragments | 1 | 2006 | 215 | 0.020 |
Why?
| Interleukin-1 | 1 | 2005 | 104 | 0.020 |
Why?
| Interleukin-10 | 1 | 2005 | 84 | 0.020 |
Why?
| Blood Proteins | 1 | 2005 | 82 | 0.020 |
Why?
| Stress, Psychological | 1 | 2007 | 260 | 0.020 |
Why?
| 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) | 1 | 2003 | 2 | 0.010 |
Why?
| Diet, Protein-Restricted | 1 | 2003 | 8 | 0.010 |
Why?
| Acidosis | 1 | 2003 | 40 | 0.010 |
Why?
| Complement System Proteins | 1 | 2003 | 46 | 0.010 |
Why?
| Food Additives | 1 | 2003 | 9 | 0.010 |
Why?
| Organic Chemicals | 1 | 2003 | 13 | 0.010 |
Why?
| Protein Array Analysis | 1 | 2003 | 23 | 0.010 |
Why?
| Caspases | 1 | 2003 | 104 | 0.010 |
Why?
| Combined Modality Therapy | 1 | 2003 | 637 | 0.010 |
Why?
| Retrospective Studies | 1 | 2011 | 6108 | 0.010 |
Why?
| Child, Preschool | 1 | 2003 | 3871 | 0.010 |
Why?
|
|
Ferrando's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|